621 results on '"Cibula, David"'
Search Results
2. DNA methylation at quantitative trait loci (mQTLs) varies with cell type and nonheritable factors and may improve breast cancer risk assessment
3. A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations
4. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors
5. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*
6. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas
7. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
8. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
9. Microsatellite instability in non-endometrioid ovarian epithelial tumors: a study of 400 cases comparing immunohistochemistry, PCR, and NGS based testing with mutation status of MMR genes
10. Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance
11. The polycystic ovary syndrome: the first 150 years of study
12. Role of adjuvant therapy in intermediate-risk cervical cancer patients – Subanalyses of the SCCAN study
13. Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories
14. Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock
15. DNA methylation-based detection and prediction of cervical intraepithelial neoplasia grade 3 and invasive cervical cancer with the WID™-qCIN test
16. The DNA methylome of cervical cells can predict the presence of ovarian cancer
17. Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock
18. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples
19. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
20. Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents
21. International expert consensus on the surgical anatomic classification of radical hysterectomies
22. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
23. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
24. Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial – SENTIX
25. Survival associated with extent of radical hysterectomy in early-stage cervical cancer: a subanalysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study
26. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial
27. Tumour-free distance: a novel prognostic marker in patients with early-stage cervical cancer treated by primary surgery
28. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
29. Ten years of live surgical broadcast at Charité-MAYO conferences (2010–2019): a systematic evaluation of the surgical outcome
30. Direct mailing of HPV self-sampling kits to women aged 50-65 non-participating in cervical screening in the Czech Republic.
31. Consensus on surgical technique for sentinel lymph node dissection in cervical cancer.
32. Plasma cell‐free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case‐control study and an ovarian cancer screening trial.
33. The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023).
34. HPV testing as an effective triage strategy in the follow-up after fertility-sparing treatment for glandular lesions of the uterine cervix.
35. Quality of training in cervical cancer radical surgery: a survey from the European Network of Young Gynaecologic Oncologists (ENYGO)
36. Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation
37. SUCCOR cone study: conization before radical hysterectomy
38. Pathologic Protocols for Sentinel Lymph Nodes Ultrastaging in Cervical Cancer
39. Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTIlity Sparing Surgery retrospective multicenter study
40. The association among cervical, anal, and oral HPV infections in high-risk and low-risk women
41. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study
42. European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma
43. Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions
44. Response to: Correspondence on 'ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors' by Thomassin-Nagarra et al
45. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
46. Determining post-operative morbidity and mortality following gynecological oncology surgery: protocol for a multicenter, international, prospective cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative—GO SOAR)
47. Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators
48. Surgical treatment of “intermediate risk” lymph node negative cervical cancer patients without adjuvant radiotherapy—A retrospective cohort study and review of the literature
49. The genetic landscape of 87 ovarian germ cell tumors
50. Sonographic, Demographic, and Clinical Characteristics of Pre- and Postmenopausal Women with Endometrial Cancer; Results from a Post Hoc Analysis of the IETA4 (International Endometrial Tumor Analysis) Multicenter Cohort.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.